ArticleJournal of thrombosis and haemostasis : JTH2011
The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model.
Article in Journal of thrombosis and haemostasis : JTH, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Method parameters' impact on mortality and variability in mouse stroke experiments: a meta-analysis.Scientific reports · 2016Pooled it
- Cell-Specific Mechanisms in the Heart of COVID-19 Patients.Circulation research · 2023Review
- Article
- Interleukin-1 receptor inhibition reduces stroke size in a murine model of sickle cell disease.Haematologica · 2021Article
- Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential.Critical care (London, England) · 2019Review
- Protective effects of atorvastatin on cerebral vessel autoregulation in an experimental rabbit model of subarachnoid hemorrhage.Molecular medicine reports · 2018Article
- Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke.Acta neuropathologica · 2017Article
- Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Recombinant Thrombomodulin (Solulin) Ameliorates Early Intestinal Radiation Toxicity in a Preclinical Rat Model.Radiation research · 2016Article
- Dual targeting of therapeutics to endothelial cells: collaborative enhancement of delivery and effect.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- Review
- Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.Physiological reviews · 2013Article
- Thrombomodulin and the vascular endothelium: insights into functional, regulatory, and therapeutic aspects.American journal of physiology. Heart and circulatory physiology · 2013Review
- Article
- Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity.Nature medicine · 2012Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundCurrently there is no approved anticoagulant for treating acute stroke. This is largely because of concern for hemorrhagic complications, and suggests a critical need for safer anticoagulants. Solulin is a soluble analog of the endothelial cell receptor thrombomodulin, able to bind free thrombin and convert it to an activator of the anticoagulant, protein C.
objectiveSolulin was tested for its ability to inhibit middle cerebral artery occlusion (MCAO) induced by photothrombosis, and to restore MCA patency after establishment of stable occlusion.
methodsCerebral blood flow (CBF) was monitored by laser Doppler for 1.5 h after occlusion and again 72 h later.
resultsSolulin treatment 30 min before thrombosis resulted in an approximately 50% increase in time to form a stable occlusion. When administered 30 or 60 min after MCAO, Solulin significantly improved CBF within 90 min of treatment. In contrast, none of the vehicle-treated mice showed restoration of CBF in the first 90 min and only 17% did so by 72 h. Solulin treatment was associated with a significant reduction in infarct volume, and was well tolerated with no overt hemorrhage observed in any treatment group. Mechanistic studies in mice homozygous for the factor (F)V Leiden mutation, suggest that Solulin's efficacy derives primarily from the anticoagulant activity of the thrombin-Solulin complex and not from direct anti-inflammatory or neuroprotective effects of Solulin or activated protein C.
conclusionsOur data indicate that Solulin is a safe and effective anticoagulant that is able to antagonize active thrombosis in acute ischemic stroke, and to reduce infarct volume.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.